Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. (XLO): 3 pipeline candidates · ~21 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
20.5 months
D/E 1.25 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
2 buys · 2 sells (180d)
A transparent, data-derived signal for Xilio Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$54.8M
Cash
$152.1M
Quarterly Burn
$22.3M
Runway
20.5 mo
Revenue
$12.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| vilastobart | Phase 1/Phase 2 |
| xtx202 | Phase 1/Phase 2 |
| xtx301 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$5.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 247,320 | $2.1M |
| caligan partners lp | 112,128 | $943K |
| morgan stanley | 57,493 | $484K |
| renaissance technologies llc | 49,566 | $417K |
| aju ib investment co., ltd. | 47,695 | $401K |
| geode capital management, llc | 37,197 | $313K |
| fmr llc | 36,558 | $307K |
| vanguard fiduciary trust co | 28,475 | $239K |
| velan capital investment management lp | 14,285 | $120K |
| ghisallo capital management llc | 13,800 | $116K |
Showing top 10 of 18 institutional holders of Xilio Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Xilio Therapeutics, Inc.'s pipeline?
Xilio Therapeutics, Inc. (XLO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Xilio Therapeutics, Inc.'s lead drug candidate?
Xilio Therapeutics, Inc.'s most advanced tracked candidate is vilastobart (Phase 1/Phase 2) for Advanced Solid Tumor.
What is Xilio Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Xilio Therapeutics, Inc. has approximately 20.5 months of cash runway.
What is Xilio Therapeutics, Inc.'s market capitalization?
Xilio Therapeutics, Inc.'s market capitalization is approximately $54.8M.
Who is the CEO of Xilio Therapeutics, Inc.?
Dr. Rene Russo BCPS, Pharm.D. is the chief executive officer of Xilio Therapeutics, Inc. (XLO).
Get the full picture on Xilio Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.